IL1A and colitis: Interestingly, SIGIRR has more recently been shown to block TH17 cell proliferation by antagonizing IL-1 signaling and glycolytic metabolism, a finding which may have particular importance in the context of spontaneous colitis which develops in Il10−/− mice and in which TH17 cells can mediate significant pathology (67).